PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer
In this MEDtalk Eric Pujade-Lauraine present the key results of the study retreatment with maintenance olaparib in patients with ovarian cancerpreviously treated with a PARP inhibitor.